BioCentury | Mar 16, 2021
Product Development

March 16 COVID Quick Takes: FDA launches adverse events dashboard; plus Kintor, Boehringer, Apeiron, Moderna and more

FDA launched an FDA Adverse Event Reporting System (FAERS) public dashboard for COVID-19 drugs and biologics with emergency use authorization (EUA). The launch comes as EMA’s Pharmacovigilance Risk Assessment...
BioCentury | Jan 1, 2021
Targets & Mechanisms

A snapshot of target innovation in 2020

Preclinical publications highlighted in BioCentury’s Distillery this year identified white space target opportunities including untapped E3 ubiquitin ligases, vesicular regulators and ion channels, as...
BioCentury | Oct 31, 2020
Product Development

Oct. 30 Quick Takes: Aducanumab heads to EMA; plus Boehringer, Arcus-AZ, Tricida

EMA accepts aducanumab MAA for reviewBiogen Inc. (NASDAQ:BIIB) and Eisai Co. Ltd. (Tokyo:4523) said the EMA accepted for review an MAA for Alzheimer’s disease candidate aducanumab. The anti-amyloid mAb will undergo standard review, putting a...
BioCentury | Oct 28, 2020
Distillery Therapeutics

Targeting the NMDA receptor-TRPM4 complex for neurodegeneration

DISEASE CATEGORY: Neurology INDICATION: Stroke; neurology Disruption of the NMDA receptor-TRPM4 complex could treat ischemic stroke and other neurodegenerative diseases with NMDA receptor involvement. In mouse hippocampal neurons deprived of oxygen and glucose or treated...
BioCentury | Jul 1, 2020

Goldfinch’s $100M round sets up Third Rock company to advance kidney disease therapies

With $100 million in series B funding, Goldfinch Bio Inc. aims to move its second kidney disease therapy into the clinic and begin Phase II testing of its lead candidate. Eventide Asset Management led the...
BioCentury | Mar 7, 2020
Product Development

If NoNO’s stroke trial strategy pays off, it could bring the first new therapy in a generation

Building on decades of work on a new mechanism, NoNO Inc. is laying the groundwork for an FDA approval in stroke, a notoriously difficult indication that hasn’t seen a new therapy in almost 25 years....
BioCentury | Oct 3, 2019
Product Development

Kidney is the new liver: why kidney indications are coming into sharp focus

Interest in kidney diseases is mounting among investors, biotechs and pharmas at a rate reminiscent of the liver disease explosion almost a decade ago. The momentum is driven by improvements at both ends of the...
BioCentury | Sep 13, 2019

After single exit, Avalon seeks path forward for build-to-buy assets from GSK deal

With GSK effectively bowing out of a 2013 build-to-buy deal with Avalon Ventures after delivering just one exit, the VC is seeking to navigate a future for a handful of Phase I-ready programs it created...
BioCentury | Aug 8, 2019
Translation in Brief

A cool menthol switch for gene expression

...of gene and cell therapies (see "Making Cells Compute" ). The team took advantage of TRPM8’s...
...activated T cells; TRPM8 - Transient receptor potential cation channel subfamily M member 8 Mary Romeo, Assistant Editor ETH Zurich Senti Biosciences Inc. Activin receptor type 2B (ACVR2B) Insulin Transient receptor potential cation channel subfamily M member 8 (TRPM8) Diabetes Martin...
BioCentury | Aug 8, 2019
Distillery Therapeutics

Engineered cells with a synthetic gene switch for diabetes

...the insulin gene. In Type I diabetic mice, topical menthol application activated the ion channel TRPM8...
...hyperglycemia in the mice (see "A Cool Menthol Switch for Gene Expression" ). TARGET/MARKER/PATHWAY: Insulin; transient receptor potential cation channel subfamily M member 8 (TRPM8)... July 8, 2019 doi:10.1038/s41591-019-0501-8 CONTACT: Martin Fussenegger, ETH Zurich, Basel, Switzerland e-mail: Mary Romeo ETH Zurich Insulin Transient receptor potential cation channel subfamily M member 8 (TRPM8) Diabetes...
Items per page:
1 - 10 of 45